Not specific to RAC or bisantrene, but as just another retail shareholder..
2 Questions if you don’t mind.
Just in general speaking terms, If i brought a drug off the shelf & started up XYZ biotech Australia. And it turns out theres utility, interest, & clinical need across many continents.
1. Would my smartest commercialisation strategy be targeting a specific indication in a specific country first, to let’s say set the pricing benchmark, before rolling it out to other countries or indications?
2. And let’s say I had 5 possible indications to go after, all each with very different company outcomes: To strike a balance between extracting as much value for my shareholders, where does pricing & size of market of a drug rank when considering a path to commercial outcome?
1. Paths to approval
2. TAM
3. Risk
4. competition
5. patient need
6. Pricing
7. other
General Comments / Chat, page-8673
-
- There are more pages in this discussion • 2,809 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.68 |
Change
-0.020(1.18%) |
Mkt cap ! $282.9M |
Open | High | Low | Value | Volume |
$1.69 | $1.69 | $1.66 | $65.89K | 39.52K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 397 | $1.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.68 | 4523 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 397 | 1.670 |
2 | 9149 | 1.655 |
6 | 49533 | 1.650 |
3 | 9200 | 1.640 |
1 | 6000 | 1.630 |
Price($) | Vol. | No. |
---|---|---|
1.680 | 4523 | 1 |
1.685 | 5085 | 1 |
1.690 | 3000 | 1 |
1.700 | 4967 | 4 |
1.715 | 532 | 1 |
Last trade - 12.52pm 18/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |